Fig. 5: Investigation of patients with longitudinal biopsies in a clinico-genomic database.

a A schematic representing the cohort of 196 patients receiving multiple, longitudinal comprehensive genomic profiling tests, with real-world clinical and outcome data matched from Flatiron Health evaluated in this study. b Patterns of acquired short variants (e.g., point mutations, indels) in the overall cohort (top), and based on specific treatment interventions (bottom), revealed treatment-specific patterns of acquired alterations. Acquired alterations (y-axis) are colored based on the type of alteration for each gene (x-axis). The therapy groups include the following—endocrine therapy (ET) and Cyclin-dependent kinase inhibitors (CDK4/6i), endocrine therapy (ET), HER2-targeted therapy (antibody (Ab)-drug conjugates, tyrosine kinase inhibitors (TKI)), Poly adenosine diphosphate-ribose polymerase inhibitors (PARPi) mono/combo therapy. c Three representative patient journeys, displaying the utility of LBx during the course of care, are shown (time shown in months, mo). Shared alterations across biopsies are shown in red. Alterations unique to a specific biopsy are shown in blue while alterations not targeted on other platforms are shown in gray.